Form 4: Immix Biopharma Director Carey Ng Reports Transaction

Director Carey Ng reports a transaction involving Immix Biopharma stock options and shares.

Summary

• Carey Ng, a director of Immix Biopharma, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the disposition of 10,000 common stock shares.
• Ng indirectly owns 1,025,221 common stock shares through Mesa Verde Venture Partners III, LP.
• Ng was granted two stock option awards to purchase 21,587 and 25,512 shares of common stock at an exercise price of $2.47 on May 15, 2024.
• The stock options vest in thirteen equal monthly installments following the grant date, contingent upon continued service with the Issuer.
• The options expire on May 26, 2033.
• The options were issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Negatives

• The report indicates the disposition of 10,000 common stock shares.

Industry Context

Form 4 filings are standard disclosures required by the SEC for company insiders, providing transparency into their transactions and holdings.

Stakeholder Impact

• Shareholders are informed about the transactions of a company insider.

Key Dates